Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Harnessing preclinical mouse models to inform human clinical cancer trials.

Gutmann DH, Hunter-Schaedle K, Shannon KM.

J Clin Invest. 2006 Apr;116(4):847-52. Review.

2.

Mouse cancer models as a platform for performing preclinical therapeutic trials.

Weiss B, Shannon K.

Curr Opin Genet Dev. 2003 Feb;13(1):84-9. Review.

PMID:
12573440
3.

Harnessing genetically engineered mouse models for preclinical testing.

Robles AI, Varticovski L.

Chem Biol Interact. 2008 Jan 30;171(2):159-64. Epub 2007 Feb 8. Review.

PMID:
17362899
4.

Predictive in vivo animal models and translation to clinical trials.

Cook N, Jodrell DI, Tuveson DA.

Drug Discov Today. 2012 Mar;17(5-6):253-60. Review.

PMID:
22493784
5.

Xenograft models for the preclinical evaluation of new therapies in acute leukemia.

Lee EM, Bachmann PS, Lock RB.

Leuk Lymphoma. 2007 Apr;48(4):659-68. Review.

PMID:
17454623
6.

Conditional mouse models of cancer.

Vignjevic D, Fre S, Louvard D, Robine S.

Handb Exp Pharmacol. 2007;(178):263-87. Review.

PMID:
17203659
7.

Using genetically engineered mouse models of cancer to aid drug development: an industry perspective.

Singh M, Johnson L.

Clin Cancer Res. 2006 Sep 15;12(18):5312-28. Review.

8.

Preclinical predictors of clinical safety: opportunities for improvement.

Sistare FD, DeGeorge JJ.

Clin Pharmacol Ther. 2007 Aug;82(2):210-4. Epub 2007 May 16. Review.

PMID:
17507920
9.

Utility of animal models for identification of potential therapeutics for rheumatoid arthritis.

Hegen M, Keith JC Jr, Collins M, Nickerson-Nutter CL.

Ann Rheum Dis. 2008 Nov;67(11):1505-15. Epub 2007 Nov 29. Review.

PMID:
18055474
10.

The use of xenograft models for the selection of cancer treatments with the EGFR as an example.

Troiani T, Schettino C, Martinelli E, Morgillo F, Tortora G, Ciardiello F.

Crit Rev Oncol Hematol. 2008 Mar;65(3):200-11. Review.

PMID:
18389522
11.

New therapeutic advances in the management of progressive thyroid cancer.

Woyach JA, Shah MH.

Endocr Relat Cancer. 2009 Sep;16(3):715-31. doi: 10.1677/ERC-08-0335. Epub 2009 Feb 13. Review.

12.

Novel molecular-targeted therapeutics for the treatment of cancer.

Yasui H, Imai K.

Anticancer Agents Med Chem. 2008 Jun;8(5):470-80. Review.

PMID:
18537530
13.

Mouse Models of Human Cancers Consortium Workshop on Nervous System Tumors.

Gutmann DH, Maher EA, Van Dyke T.

Cancer Res. 2006 Jan 1;66(1):10-3.

14.

Improving the evaluation of new cancer treatments: challenges and opportunities.

Rothenberg ML, Carbone DP, Johnson DH.

Nat Rev Cancer. 2003 Apr;3(4):303-9. Review.

PMID:
12671669
15.

Preclinical models for pediatric solid tumor drug discovery: current trends, challenges and the scopes for improvement.

Kumar S, Mokhtari RB, Yeger H, Baruchel S.

Expert Opin Drug Discov. 2012 Nov;7(11):1093-106. doi: 10.1517/17460441.2012.722077. Epub 2012 Sep 24. Review.

PMID:
22998522
16.

In vivo models of childhood leukemia for preclinical drug testing.

Bachmann PS, Lock RB.

Curr Drug Targets. 2007 Jun;8(6):773-83. Review.

PMID:
17584033
17.

Nanoparticle therapeutics: an emerging treatment modality for cancer.

Davis ME, Chen ZG, Shin DM.

Nat Rev Drug Discov. 2008 Sep;7(9):771-82. doi: 10.1038/nrd2614. Review.

PMID:
18758474
18.

Biological surrogate end-points in cancer trials: potential uses, benefits and pitfalls.

Cooper R, Kaanders JH.

Eur J Cancer. 2005 Jun;41(9):1261-6. Review.

PMID:
15939261
19.

Neuroimaging outcomes in clinical trials in Alzheimer's disease.

Frisoni GB, Delacourte A.

J Nutr Health Aging. 2009 Mar;13(3):209-12. Review.

PMID:
19262955
20.

Some thoughts on experimental screening.

Carter SK.

Biomedicine. 1975 Jan;22(1):5-17.

PMID:
1101978

Supplemental Content

Support Center